Sugi Predict

Sugi Predict / Compounds / SCHEMBL4334739

SCHEMBL4334739

SCHEMBL4334739

O=C(O)c1c[nH]c2c([N+](=O)[O-])cccc2c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DNA2 P51530 1/20 1.00
▸ CASP6 P55212 1/20 1.00
▸ CTDSP1 Q9GZU7 1/20 1.00
▸ CSNK2A2 P19784 3/20 0.57
▸ CSNK2B P67870 3/20 0.57
▸ CSNK2A1 P68400 3/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ GUSB P08236 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ FBP1 P09467 4/20 0.48
▸ TSHR P16473 1/20 0.48
▸ TET2 Q6N021 1/20 0.47
▸ TET1 Q8NFU7 1/20 0.47
▸ APEX1 P27695 1/20 0.46
▸ PARP1 P09874 1/20 0.46
▸ CDK2 P24941 1/20 0.44
▸ DYRK1A Q13627 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1277854 0.91 DNA2 (0.83) DNA2CASP6CTDSP1KDM4EALDH1A1
SCHEMBL6537720 0.87 DNA2 (0.78) DNA2CASP6CTDSP1CSNK2A2CSNK2B
SCHEMBL19220845 0.84 DNA2 (0.72) DNA2CASP6CTDSP1KDM4EALDH1A1
SCHEMBL19220852 0.83 DNA2 (0.71) DNA2CASP6CTDSP1GUSB
SCHEMBL6538006 0.81 DNA2 (0.68) DNA2CASP6CTDSP1KDM4EALDH1A1
SCHEMBL4739348 0.81 CLEC4M (0.71) DNA2CASP6CTDSP1KDM4EALDH1A1
SCHEMBL3249310 0.80 DNA2 (0.67) DNA2CASP6CTDSP1KDM4EALDH1A1
SCHEMBL8790508 0.80 DNA2 (0.67) DNA2CASP6CTDSP1KDM4EFBP1
SCHEMBL18589537 0.80 CSNK2A2 (0.69) DNA2CASP6CTDSP1CSNK2A2CSNK2B
SCHEMBL3066032 0.79 DNA2 (0.66) DNA2CASP6CTDSP1ALDH1A1GUSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780815-B2 DNA2 inhibitors for cancer treatment CITY OF HOPE (US) 2023-10-10 — — US disclosed
US-11780815-B2 DNA2 inhibitors for cancer treatment CITY OF HOPE (US) 2023-10-10 — — US disclosed
US-11198675-B2 DNA2 inhibitors for cancer treatment CITY OF HOPE (US) 2021-12-14 — — US disclosed
US-20200148645-A1 DNA2 INHIBITORS FOR CANCER TREATMENT CITY OF HOPE 2020-05-14 — — US disclosed
US-10562856-B2 DNA2 inhibitors for cancer treatment CITY OF HOPE (US) 2020-02-18 — — US disclosed
US-20190092732-A1 DNA2 INHIBITORS FOR CANCER TREATMENT CITY OF HOPE 2019-03-28 — — US disclosed
US-10173984-B2 DNA2 inhibitors for cancer treatment CITY OF HOPE (US) 2019-01-08 — — US disclosed
US-20180134664-A1 DNA2 INHIBITORS FOR CANCER TREATMENT CITY OF HOPE 2018-05-17 — — US disclosed
US-20180134664-A1 DNA2 INHIBITORS FOR CANCER TREATMENT CITY OF HOPE 2018-05-17 — — US disclosed
US-9932310-B2 DNA2 inhibitors for cancer treatment CITY OF HOPE (US) 2018-04-03 — — US disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 — — EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 — — EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 — — US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 — — US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 — — EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 — — EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 — — WO disclosed
US-4404201-A N-/ /ALKANOYLAMINOALKANOYLAMINO OR AMINOALKANOYL AMINO/-DIHYDRO-OXO-3-QUINOLINYLCARBONYL/- DERIVATIVES WARNER-LAMBERT COMPANY (US) 1983-09-13 — — US disclosed
US-4382089-A Antibacterial amide compounds, compositions thereof and methods of using them WARNER-LAMBERT COMPANY (US) 1983-05-03 — — US disclosed
US-4374138-A PENICILLINS WARNER-LAMBERT COMPANY (US) 1983-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK DNA2 4769/4885CASP6 3746/4885CTDSP1 4127/4885
US-20180134664-A1 DNA2 INHIBITORS FOR CANCER TREATMENT DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885
US-10562856-B2 DNA2 inhibitors for cancer treatment DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885
US-20190092732-A1 DNA2 INHIBITORS FOR CANCER TREATMENT DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885
US-20200148645-A1 DNA2 INHIBITORS FOR CANCER TREATMENT DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885
US-11198675-B2 DNA2 inhibitors for cancer treatment DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885
US-10173984-B2 DNA2 inhibitors for cancer treatment DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885
US-11780815-B2 DNA2 inhibitors for cancer treatment DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.